← Eichor
Study identifier: NCT06961214 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

Condition: Pulmonary Disease, Chronic Obstructive  ·  Sponsor: GlaxoSmithKline

PhasePhase 3
Planned participants960
Who can joinAll sexes, 40 Years to 80 Years
Healthy volunteersNo

About this study

Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab compared as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.

This description comes directly from the study's public registry record.

Talk to the study team

US GSK Clinical Trials Call Center  ·  877-379-3718  ·  GSKClinicalSupportHD@gsk.com

EU GSK Clinical Trials Call Center  ·  +44 (0) 20 89904466  ·  GSKClinicalSupportHD@gsk.com

Always discuss trial participation with your own doctor first.

Locations (159)

GSK Investigational SiteSheffield, Alabama, United StatesRecruiting
GSK Investigational SiteAurora, Colorado, United StatesRecruiting
GSK Investigational SiteBrooksville, Florida, United StatesRecruiting
GSK Investigational SiteDoral, Florida, United StatesRecruiting
GSK Investigational SiteFort Lauderdale, Florida, United StatesRecruiting
GSK Investigational SiteMiami, Florida, United StatesRecruiting
GSK Investigational SiteMiami, Florida, United StatesRecruiting
GSK Investigational SiteMiami, Florida, United StatesRecruiting
GSK Investigational SiteMiami, Florida, United StatesRecruiting
GSK Investigational SiteMiami, Florida, United StatesRecruiting
GSK Investigational SiteMiami, Florida, United StatesRecruiting
GSK Investigational SiteMiami, Florida, United StatesRecruiting

+ 147 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06961214